Treatment-resistant depression affects four million Americans, and until now, patients have had almost no options. Dr. Steve Levine of Compass Pathways joins RTW's Stephanie Sirota to discuss COMP360, a psilocybin-based therapy for treatment-resistant depression. From the science behind rapid and durable response, to the regulatory path, reimbursement infrastructure, and what's next for PTSD, this is a rare inside look at how the most promising new chapter in psychiatric medicine gets built.

PODCAST TEAM

Producer & Director: Devon Leaver

Editor: Dominique Guerra

Production Coordinator: Ying Yu Lin

Production Support: Annabelle Chan

Research Consultant: Connor Williams

Executive Editorial Advisor: Stephanie Sirota

Theme Music: Yehezkel Raz

Additional Music: APM Music

Featuring: Steve Levine, Chief Patient Officer of Compass Pathways, moderated by Stephanie Sirota, Partner and Chief Business Officer.

Don't forget to listen to part 1 of Stephanie's discussion, Psilocybin: Counterculture to Cutting-Edge Psychiatry.

FOLLOW US

Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.

To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify, Apple Podcasts, Amazon Music, and most other podcast platforms.

CHAPTERS

00:00 - Introduction

1:37 – Steve Levine & Compass Pathways

5:27 - The Treatment Resistant Depression Journey

9:42 - Who are the TRD Patients?

11:06 - Holding Psychedelics to the Same Standard

18:25 - Why PTSD Is the Next Frontier

21:01 - Lifestyle's Role in Treatment Durability

22:41 - Outro

DISCLAIMER

This interview was given by Steve Levine, Chief Patient Officer of Compass Pathways, and moderated by Stephanie Sirota, Partner and Chief Business Officer at RTW Investments. Statements reflect RTW's views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results. The views expressed by guests are their own, and their appearance on the program does not imply an endorsement of them or any entity they represent.